MENS: Jyong Biotech Corp Company Value to Net Income

Corporate emblem and logo of Jyong Biotech Limited (MENS)

Analyzing the P/E trend for Jyong Biotech Ltd (MENS) on GURU.Markets, we note that -28.20 serves as the current metric level. The financial stability of Jyong Biotech Ltd is currently minimal due to R&D expenditures. Growth is based on partnerships with Asian centers and distribution acquisition deals; however, prolonged regulatory approval for plant-based drugs and pressure from synthetic analogs create significant risks.

MENS Jyong Bio: Price to Earnings Ratio in the range 06/21/2025 - 11/16/2026

Comprehensive metric breakdowns and analytics for Jyong Biotech Limited (MENS)

- price and consensus price forecast:
Comprehensive company analysis:Jyong Biotech Limited - MENS
Flagship merchandise of Jyong Biotech

When constructing a defensive portfolio, fundamental screening relies on the market capitalization to net income ratio, which determines the cost per unit of a corporation's real income. For Jyong Biotech Ltd (MENS), which invests in a highly qualified staff of biologists and laboratories, the company's historical P/E dynamics allow investors to filter out manipulative price fluctuations and identify hidden asset accumulation by major players.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Ligand Pharmaceuticals Incorporated LGND|Amneal (AMRX) - Market Cap to Earnings|PRGO: Price to Earnings Ratio|Alvotech SA - Market Price to Net Income Ratio|LQDA: P/E Multiple|Galapagos Genomics - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)